131 related articles for article (PubMed ID: 2841741)
1. [Enoxaparin in the prevention of thrombosis of extracorporeal circulation during dialysis of patients with chronic renal failure].
Pouzol P; Dechelette E; Jurkovitz C; Kuentz F; Polack B
Rev Med Interne; 1988; 9(3):321-6. PubMed ID: 2841741
[TBL] [Abstract][Full Text] [Related]
2. [Antithrombotic activity of low molecular weight heparin (enoxaparin) during hemodialysis in patients with terminal kidney failure].
Przedlacki J; Bogdańska-Straszyńska B; Sawicka B; Włodarczyk D; Sladowska B; Ajewski M; Wasiak K; Gellert R
Pol Arch Med Wewn; 1994 Jun; 91(6):438-45. PubMed ID: 7971464
[TBL] [Abstract][Full Text] [Related]
3. [Anticoagulation of the extracorporeal circuit in chronic hemodialysis].
Ryckelynck JP; Chouraqui D; Lobbedez T
Nephrologie; 1998; 19(4):223-5. PubMed ID: 9675763
[TBL] [Abstract][Full Text] [Related]
4. [Simple coagulation prophylaxis using low-molecular heparin enoxaparin in pediatric hemodialysis].
Bianchetti MG; Speck S; Müller R; Oetliker OH
Schweiz Rundsch Med Prax; 1990 Jun; 79(23):730-1. PubMed ID: 2164251
[TBL] [Abstract][Full Text] [Related]
5. Arterial line versus venous line administration of low molecular weight heparin, enoxaparin for prevention of thrombosis in the extracorporeal blood circuit of patients on haemodialysis or haemodiafiltration: A randomized cross-over trial.
Kurtkoti J; Bose B; Hiremagalur B; Sun J; Cochrane T
Nephrology (Carlton); 2016 Aug; 21(8):663-8. PubMed ID: 26609786
[TBL] [Abstract][Full Text] [Related]
6. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
7. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials.
Lim W; Cook DJ; Crowther MA
J Am Soc Nephrol; 2004 Dec; 15(12):3192-206. PubMed ID: 15579523
[TBL] [Abstract][Full Text] [Related]
9. [Enoxaparin in haemodialysis].
Olszowska A; Zelichowski G
Pol Merkur Lekarski; 2002 Nov; 13(77):433-6. PubMed ID: 12621768
[TBL] [Abstract][Full Text] [Related]
10. The safety of heparins in end-stage renal disease.
Sonawane S; Kasbekar N; Berns JS
Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408
[TBL] [Abstract][Full Text] [Related]
11. [Use in hemodialysis and hemofiltration of CY 216 (Fraxiparine) administered via intravenous bolus in patients with acute and chronic renal insufficiency with and without hemorrhagic risk].
Steinbach G; Bosc C; Caraman PL; Azoulay E; Olry L; D'Azemar P; Chopin J
Nephrologie; 1990; 11(1):17-21. PubMed ID: 2165223
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of a low molecular weight heparin (reviparine) in hemodialyzed patients.
Baumelou A; Singlas E; Petitclerc T; Desmichels D; Jacobs C; Soria J
Nephron; 1994; 68(2):202-6. PubMed ID: 7830857
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the anticoagulant effect of low-molecular-weight heparins based on the anti-Xa level during haemodialysis.
Tao M; Zheng D; Liang X; Ye M; Liu Y; Li Y; Shen H; He Q
Nephrology (Carlton); 2020 Sep; 25(9):723-729. PubMed ID: 31999031
[TBL] [Abstract][Full Text] [Related]
14. Low-molecular-weight heparin for routine hemodialysis.
Davenport A
Hemodial Int; 2008 Oct; 12 Suppl 2():S34-7. PubMed ID: 18837768
[TBL] [Abstract][Full Text] [Related]
15. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
Lavaud S; Canivet E; Wuillai A; Maheut H; Randoux C; Bonnet JM; Renaux JL; Chanard J
Nephrol Dial Transplant; 2003 Oct; 18(10):2097-104. PubMed ID: 13679486
[TBL] [Abstract][Full Text] [Related]
16. Haemodialysis in patients treated with oral anticoagulant: should we heparinize?
Krummel T; Scheidt E; Borni-Duval C; Bazin D; Lefebvre F; Nguyen P; Hannedouche T
Nephrol Dial Transplant; 2014 Apr; 29(4):906-13. PubMed ID: 24459138
[TBL] [Abstract][Full Text] [Related]
17. The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane.
Chanard J; Lavaud S; Maheut H; Kazes I; Vitry F; Rieu P
Nephrol Dial Transplant; 2008 Jun; 23(6):2003-9. PubMed ID: 18156457
[TBL] [Abstract][Full Text] [Related]
18. Comparison of effects of different heparins on thrombin activatable fibrinolysis inhibitor in hemodialyzed patients.
Małyszko J; Małyszko JS; Hryszko T; Pawlak K; Myśliwiec M
Am J Nephrol; 2004; 24(6):624-9. PubMed ID: 15627717
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of four modes of low-dose anticoagulation during intermittent haemodialysis.
Skagerlind MSE; Stegmayr BG
Eur J Clin Pharmacol; 2018 Mar; 74(3):267-274. PubMed ID: 29198062
[TBL] [Abstract][Full Text] [Related]
20. Practical Value of Anti-Xa Activity in the Evaluation of Extracorporeal Circuit Anticoagulation during Haemodialysis: Results of a Cross-Sectional Single-Centre Study.
Coene KLM; Dekker MJE; Kerskes MCHM; Hengst M; Schonck MJM; Konings CJAM; Scharnhorst V
Nephron; 2017; 137(3):205-211. PubMed ID: 28817831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
